心血管

订阅

MedSci主页 / 所有栏目 / 心血管

2018AHA热点持续升温！PCSK9抑制剂再添新证

2018-11-13 中国心血管健康联盟进阶学院 MedSci原创

抑制剂
关注

AHA科学年会如火如荼的进行当中，PCSK9抑制剂作为本次大会讨论的热点之一，亦有众多精彩内容呈现！

AHA科学年会如火如荼的进行当中，PCSK9抑制剂作为本次大会讨论的热点之一，亦有众多精彩内容呈现！

FOURIER亚组研究分析：PCSK9抑制剂对于存在MI病史患者的临床获益

FOURIER研究已为大众所熟知，依洛尤单抗在他汀治疗的基础上进一步降低LDL-C水平约60%。本次大会上，Marc Sabatine教授对FOURIER研究的亚组分析进行了汇报，分析纳入了22,351例既往发生MI的患者（总体队列的81%），针对三个特征将患者进行分组，包括既往发生MI的时间、基线时发生MI的次数以及基线时是否存在残余多支血管病变，在组间比较依洛尤单抗与安慰剂的疗效，并对患者的CV死亡、MI和卒中风险进行分析。

研究显示既往2年以内发生MI、MI发生次数2次以上和多血管病变均是CV死亡、MI和卒中的危险因素。而对于这些风险较高的患者，采用依洛尤单抗的获益更大。

在既往2年内发生MI的患者中，依洛尤单抗可降低相对风险24%，绝对风险2.9%。


同样的，在既往发生2次以上（含）MI的患者中，依洛尤单抗可降低相对风险21%，绝对风险2.6%。


对于合并多支血管病变的患者，依洛尤单抗的疗效更为显著，可降低相对风险30%，绝对风险3.4%。


Sabatine教授指出至少存在一个高危因素的患者占了亚组分析整体人群的63%。综合来看，存在1个以上（含）高风险因素的患者，依洛尤单抗治疗可降低相对风险22%，绝对风险2.5%。Landmark分析同样显示，依洛尤单抗治疗的获益在1年后更为显著。


总而言之，该亚组分析验证了依洛尤单抗对于既往存在MI病史患者的获益，特别是对于那些心血管事件高风险的患者，获益尤为显著。

亚洲人群使用PCSK9抑制剂获益

FOURIER研究和GLAGOV研究显示出PCSK9抑制剂对于缺血性心脏病患者的疗效。对于ASCVD二级预防而言，高风险患者应将LDL-C水平控制在70mg/dL以下。然而对于杂合子型家族性高胆固醇血症（HeFH）患者，通过传统的降脂药物很难达到这一靶标。来自东京的Sato教授在本次大会上发表了一篇研究，评估了PCSK9抑制剂在高风险HeFH患者中的疗效。

研究纳入了存在多种风险因素的HeFH患者，如既往CVD病史、男性35岁以上、女性45岁以上、TG＞150mg/dL、HDL-C＜40mg/dL、Lp(a)＞50mg/dL、跟腱黄色瘤＞15mm、吸烟、糖尿病、高血压或慢性肾病患者。对于无法获得理想LDL-C水平且已经接受最大耐受剂量他汀的患者采用PCSK9抑制剂治疗。同时，研究分析一级预防和二级预防的临床进程、临床特征、实验室生化数据、体格检查等。HeFH患者中位年龄59.4±13.2岁、BMI26.9±4.1kg/m2。研究发现，在接受PCSK9抑制剂治疗4周后，T-C、LDL-C、ApoB、Lp(a)和氧化LDL-C水平均有显著改善，治疗24周后颈动脉内膜中层厚度（IMT）、冠状动脉斑块显著消退。

PCSK9抑制剂除了可显著降低高风险HeFH患者血脂水平，同时改善了斑块形成，可预防未来心血管事件发生。


PCSK9抑制剂对于心肌缺血/再灌注损伤导致的脑损伤具有神经保护作用

心肌缺血/再灌注损伤（I/R）不仅会减少脑血流，同时会引起大脑线粒体功能异常，微神经胶质功能亢进和降低树突棘密度。PCSK9抑制剂作为新型降胆固醇药物显示出了减少细胞凋亡和炎症的作用，来自泰国的Chattipakorn团队在本次大会上就PCSK9抑制剂对于改善心肌I/R造成脑损伤作用进行评估。

研究采用成年雄性维斯塔鼠，分为假手术组（n=4）或心肌I/R手术组（n=40）。心肌I/R小鼠进一步分为4组（每组10只）：1）媒介组；2）缺血前使用PCSK9抑制剂组（10μg/kg IV）；3）缺血中给予PCSK9抑制剂组；4）再灌注时给予PCSK9抑制剂组。最后摘除大脑评估大脑线粒体形态、微神经胶质和星形细胞活性以及树突棘密度。

心肌I/R可通过增加CD11b+/CD45+high细胞、CD11b+/CD45+low细胞、和Iba1+微神经胶质细胞和GFAP+星形胶质细胞来激活大脑固有免疫。此外心肌I/R可导致微神经胶质和星形胶质细胞功能亢进，降低树突棘密度。但研究并没有发现线粒体功能异常。只有在缺血前使用PCSK9抑制剂具有神经保护作用。该研究显示，PCSK9抑制剂不仅有降胆固醇功能，还可减少心肌I/R对大脑带来的不利影响。

 

PCSK9抑制剂自上市以来就获得了广泛的关注，其卓越的降胆固醇疗效也已获得广泛认可，本次大会上，除了持续验证了PCSK9抑制剂对于心血管高风险患者的获益之外，还显示了其可能存在降胆固醇以外的获益，显示了PCSK9抑制剂未来更广阔的应用前景。但目前这些研究仅局限于小规模临床研究或者动物研究上，还需要更多的临床研究来探索及验证其额外获益！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1685616, encodeId=951d16856167b, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Fri Dec 14 10:30:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786861, encodeId=ba6f1e8686183, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu Dec 06 19:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777272, encodeId=e0571e77272c9, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Tue Oct 22 14:30:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851839, encodeId=71fd185183981, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Feb 04 17:30:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267968, encodeId=b613126e96888, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Nov 15 08:30:00 CST 2018, time=2018-11-15, status=1, ipAttribution=)]
    2018-12-14 Tamikia

    #PCS#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1685616, encodeId=951d16856167b, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Fri Dec 14 10:30:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786861, encodeId=ba6f1e8686183, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu Dec 06 19:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777272, encodeId=e0571e77272c9, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Tue Oct 22 14:30:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851839, encodeId=71fd185183981, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Feb 04 17:30:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267968, encodeId=b613126e96888, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Nov 15 08:30:00 CST 2018, time=2018-11-15, status=1, ipAttribution=)]
    2018-12-06 wjywjy

    #PCSK9抑制#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1685616, encodeId=951d16856167b, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Fri Dec 14 10:30:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786861, encodeId=ba6f1e8686183, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu Dec 06 19:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777272, encodeId=e0571e77272c9, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Tue Oct 22 14:30:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851839, encodeId=71fd185183981, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Feb 04 17:30:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267968, encodeId=b613126e96888, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Nov 15 08:30:00 CST 2018, time=2018-11-15, status=1, ipAttribution=)]
    2019-10-22 FukaiBao

    #Csk#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1685616, encodeId=951d16856167b, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Fri Dec 14 10:30:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786861, encodeId=ba6f1e8686183, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu Dec 06 19:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777272, encodeId=e0571e77272c9, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Tue Oct 22 14:30:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851839, encodeId=71fd185183981, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Feb 04 17:30:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267968, encodeId=b613126e96888, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Nov 15 08:30:00 CST 2018, time=2018-11-15, status=1, ipAttribution=)]
    2019-02-04 jklm09

    #抑制剂#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1685616, encodeId=951d16856167b, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Fri Dec 14 10:30:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786861, encodeId=ba6f1e8686183, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Thu Dec 06 19:30:00 CST 2018, time=2018-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777272, encodeId=e0571e77272c9, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Tue Oct 22 14:30:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851839, encodeId=71fd185183981, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Feb 04 17:30:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267968, encodeId=b613126e96888, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Nov 15 08:30:00 CST 2018, time=2018-11-15, status=1, ipAttribution=)]
    2018-11-15 zhaohui6731

    #AHA#

    0

相关资讯

J Med Chem：一类具有新作用机制的选择性口服小分子HBV抑制剂

近日科学家报道了二氢喹诺酮（DHQ）衍生物的抗HBV活性以及构效关系，其中化合物RG7834是一种具有高度选择性和口服生物活性的乙肝病毒抑制剂，它能抑制病毒抗原和病毒的DNA活性，而且具有新的作用机制。

Nat Chem Bio丨李祥/李海涛合作组开发YEATS结构域抑制剂

组蛋白翻译后修饰在一系列染色质活动中扮演着极为重要的角色，也是调控表观遗传学事件的重要机制之一。在细胞内，组蛋白翻译后修饰受到其“书写器”（“Writer”）和“擦除器”（“Eraser”）的严密调节，并且通过招募其“阅读器”（“Reader”）效应蛋白来控制染色质结构及相关基因表达，从而影响DNA复制、细胞分裂、分化和凋亡等关键的细胞进程。越来越多证据表明，组蛋白修饰水平的失调以及识别的紊乱可能

Cell Res:去泛素化酶家族特异性抑制剂开发新靶点

泛素化/去泛素化是一种动态的蛋白质双向修饰调控系统，在体内由泛素连接酶（E1-E2-E3）和去泛素化酶（DUB）家族分别负责。与磷酸化/去磷酸化系统类似，通过参与细胞内众多信号通路，泛素化双向修饰决定了很多生理事件的发生发展，被认为是极具潜力的癌症及神经类等疾病的治疗新靶点。

NEJM：选择性酪氨酸激酶2抑制剂用于银屑病的2期试验

由此可见，用口服药物BMS-986165以3mg/天和更高的剂量选择性抑制TYK2治疗12周内与安慰剂相比更能有效清除牛皮癣。需要更大型和更长时间的该药物试验来确定其对银屑病患者的安全性和耐久性。

JACC：可溶性肿瘤因子2抑制剂可预测慢性心衰预后

可溶性肿瘤因子2抑制剂（sST2）是一种炎症和纤维化的生物标志物。本研究的目的旨在评估sST2在慢性心衰中的预测价值。本研究共纳入了4268名患者（平均年龄为68岁，男性占75%，65%为缺血性心衰，87%为左室射血分数（LVEF）＜40%），其NT-proBNP、hs-TnT和sST2的水平分别是1，360 ng/l (四分位数区间：513 -3，222 ng/l)， 18 ng/l (四分位数

CDK4/6抑制剂“三兄弟”，谁领风骚

内分泌治疗是绝经后激素受体阳性，HER2阴性晚期乳腺癌患者标准治疗，其中芳香化酶抑制剂（AI）是首选的一线方案。然而，绝大多数患者在治疗后都会出现内分泌抵抗和疾病进展，因此延长或重建内分泌治疗敏感性是一个重要的治疗思路。CDK4/6抑制剂是近三五年里冉冉升起的抗癌“神药”，正在迅速改变激素受体（HR）阳性人表皮生长因子受体2（HER2）阴性（HR + HER2-）晚期乳腺癌的治疗格局，有效地克